Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

NCT04447651 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Solid Tumor
SF3B1 Gene Mutation
Spliceosome Mutation
U2AF1 Gene Mutation
SRSF2 Gene Mutation

Interventions

OTHER: Recommendation for treatment with immunotherapy

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]
[object Object]